Menu

ISTOCK, SELIMAKSAN

Mitochondrial Infusions Given to Babies with Heart Damage

Among 11 infants treated to date, most survived and their heart function improved.

Jul 10, 2018
Kerry Grens

Eleven babies have been given an experimental treatment to repair damaged heart tissue: 1 billion of their own mitochondria infused into the impaired cardiac muscle. So far, The New York Times reports, eight babies have survived and their hearts are working better; in comparison, 65 percent of similar babies who don’t receive the treatment die and none experience an improvement in their cardiac function.

“They gave her a fighting chance,” Kate Bowen, the mother of one of the babies who was treated, tells The Times. Her daughter Georgia went into cardiac arrest after birth and was kept alive with a machine that operated her lungs and heart. She can now breathe on her own, although her heart has not fully recovered.

Mitochondrial transplants come from the patients’ own healthy cells in another part of the body. They are then isolated and delivered to the heart. 

Doctors who developed the technique tried it out on the first baby in 2015. The newborn had suffered heart damage during a surgery to repair a congenital defect in the heart. Within two days, The Times reports, the baby’s heart was beating normally. “It was amazing,” Sitaram Emani, the pediatric surgeon at Boston Children’s Hospital who performed the operation, tells the newspaper.

The procedure is “a really intriguing option” to test out in adults, Peter Smith, chief of cardiothoracic surgery at Duke University, tells The Times. Experiments in adults are being planned.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.